Investors Affected by Hims & Hers Health's Alleged Securities Fraud Urged to Act Quickly

Hims & Hers Health Faces Securities Fraud Class Action

Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of a securities class action lawsuit after the Federal Trade Commission (FTC) accused it of severe business misconduct. The investigation led by Hagens Berman aims to secure justice for investors who have realized significant losses during this tumultuous period.

The allegations stem from a complaint filed on July 29, 2026, where the FTC, collaborating with the State of Utah and the County of Los Angeles, highlighted multiple issues surrounding Hims’ business practices. One of the key aspects of the complaint is that despite promoting a strong commitment to protecting user data, Hims allegedly disclosed sensitive health information to third-party advertising platforms, raising serious privacy concerns. This is particularly alarming given the company's repeated assurances regarding data protection and secure client interactions.

Additionally, the lawsuit points to troubling billing practices. Hims reportedly charged consumers for prescriptions shortly after they filled out intake forms, without providing adequate medical consultations. This practice appears to violate the Restore Online Shoppers' Confidence Act (ROSCA), which mandates clear and informed consent from consumers before enrolling them in recurring subscription models.

The market had a strong reaction to these revelations, with Hims’ stock price dropping significantly—over $4 in a single day—wiping out nearly $970 million from its market capitalization. The swift decline underscores investor concerns regarding the company's financial health and ethical practices, raising questions about whether Hims transparently communicated these risks to its stakeholders.

Hagens Berman is actively calling on affected investors to step forward. Those who sustained profound losses during the class period from August 4, 2025, to July 29, 2026, are encouraged to come forward before the lead plaintiff deadline on November 2, 2026. This is particularly pertinent for individuals who may have information that could bolster the case against Hims and support the firm’s ongoing investigation.

Whistleblowers who possess non-public information related to Hims might also have avenues to contribute, with the SEC's program offering rewards up to 30 percent for information that leads to a successful recovery. Investors and potential whistleblowers are urged to contact Hagens Berman at the provided helpline or email to discuss options further.

In conclusion, the ongoing legal challenge facing Hims & Hers Health highlights the evolving landscape of corporate accountability, particularly in the burgeoning telehealth sector. As regulators scrutinize the actions of companies in this space more rigorously, the case serves as a reminder of the importance of transparency and ethical practices in maintaining investor trust and safeguarding consumer interests.